TECH OUTLOOKTECH OUTLOOKMAY - 202119and Pharma companies who aim to maximize their business opportunity in Europe. In efforts to ensure the success of orphan drug programs, ExCEEd Orphan also educates KOLs (Key Opinion Leaders) such that they become familiar with the treatments. Recognized KOLs who spread unbiased information about innovative treatments are essential for an optimal product launch and can also advocate government reimbursements for new treatment options. ExCEEd Orphan has stayed true to this method of operation, and it has resulted in the company orchestrating multiple successful projects for its clients.One such case study involved the premarketing of Zolgensma ­a gene therapy medication used to treat SMA. ExCEEd Orphan was hired by AveXis, a company that developed this gene therapy, to strategise the premarketing operations and create market access in CEE countries. Firstly, ExCEEd Orphan mapped the market and found centres in each country that could treat SMA. The company then worked with KOLs, who were instrumental in devising unique alternatives to the treatment and creating peer-to-peer discussions with the scientific community. Finally, since the treatment was available only to children of a specific weight category, ExCEEd Orphan also identified patients who met the criteria. The project was immensely successful allowing numerous children suffering from SMA to benefit from gene therapy treatment even before EMA approval. "Allowing a child with a debilitating illness to crawl and walk and slowly turn their life around after their therapy gives us one of the highest levels of job satisfaction," says a proud Hermanek.For BioTech and Pharma companies, achieving early market access simultaneously in multiple countries helps them bring innovative therapies to patients in need and also expedites early revenue generation. And this is precisely what ExCEEd Orphan provides ­ starting from market mapping and continuing with pre-approval medical communication with selected key stakeholders to recommending optimal market access strategy, negotiating reimbursement, and finishing with focused marketing and distribution. All these services result in clients gaining a highly cost-effective, impactful, and low-risk entry into the usually not easy to penetrate CEE markets. Providing ample market access for both patients and clinics is the cornerstone of our company
< Page 9 | Page 11 >